Clinical trial · Interventional
Visualising c-MET and Activated Neutrophils in Lung Cancer
Exploratory Study to Optically Visualise Activated Neutrophils and the Proto-oncogene, c-MET, in Lung Cancer Using DUAL Colour Fibre-based Endomicroscopy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): C-met marker expired
Summary
Brief summary (as posted)
Lung cancer is currently a major health problem in the UK. Despite being one of the most common cancers, lung cancer has a poor prognosis compared to other types of cancer and is the leading cause of cancer death in the world. As opposed to other organs, the lung is highly susceptible to inflammatory insults, for example from bacterial infection-induced and tobacco-induced inflammation. It has long been known that the cellular microenvironment that nurtures tumour growth and development is linked to sites of chronic inflammation but molecular insights into how external inflammation boosts or inhibits cancer in the lungs remains unclear. This study aims to directly visualise the expression of a well known marker of cancerous tissue, c-MET, and the activity of neutrophils in human lung cancer in vivo in situ using fibre-based endomicroscopy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Delivery Device Cathetar and Miniaturised imaging fibre | Device | — | UNRESOLVED |
| Optical endomicroscopy system | Device | — | UNRESOLVED |
| Optical Imaging Agents (EMI-137, NAP) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Imaging agents and imaging devices
- description
- All participants in Cohort 1 will be dosed on one occasion with the optical imaging agents and Cohort 2 can be dosed twice per agent. The final dosage will be \<100ug per agent. The agents will be delivered using a novel delivery catheter and imaged with a novel imaging fibre and microendoscopy system.
- interventionNames
- Other: Optical Imaging Agents (EMI-137, NAP)
- Device: Delivery Device Cathetar and Miniaturised imaging fibre
- Device: Optical endomicroscopy system
Primary outcomes (1)
- measure
- The measurement of optical agents in the lung
- timeFrame
- On average, fluorescence signal can be detected within 5 minutes following optical imaging agent administration.
- description
- The primary endpoint of this clinical investigation is to image the delivery of the optical imaging agents in human lung cancer using a novel delivery catheter, imaging fibre and fibre-based endomicroscopy system.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
INCLUSION CRITERIA FOR COHORT 1 • Patients undergoing cardiothoracic surgery for resection of lung cancer INCLUSION CRITERIA FOR COHORT 2 • Patients with inoperable stage 3 or 4 lung cancer INCLUSION CRITERIA FOR BOTH COHORTS * ≥ 16 years * Provision of informed consent from the patient prior to any study related procedures. * Normal electrocardiogram (ECG) * Forced Expiratory Volume (FEV1) \>1L * Thoracic CT scan taken in the last 20 weeks * Attending consultant permission for bronchoscopy * Readily accessible target areas with bronchoscopy and FE EXCLUSION CRITERIA * Refusal for participation by attending consultant * Unsuitable for bronchoscopy * Any history of anaphylaxis * Significant coagulopathy, which causes bronchoscopy to be unsuitable, as determined by clinical co-investigator or the participant's attending consultant, using information which is routinely available * Myocardial infarction in the preceding four weeks * Women who are pregnant or are breastfeeding * Receiving drugs that cause increased autofluorescence in the lung, specifically amiodorane and methotrexate * Oxygen saturation \<92% breathing room air * Platelet count \< 50 x 109/L * Bleeding diathesis
References
Publications (0)
Data not yet available